Carregant...
Miniatura

Tipus de document

Article

Versió

Versió publicada

Data de publicació

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/126453

A novel orally available inhibitor of focal adhesion signaling increases survival in a xenograft model of diffuse large B-cell lymphoma with central nervous system involvement

Títol de la revista

Director/Tutor

ISSN de la revista

Títol del volum

Resum

Central nervous system dissemination is a relatively uncommon but almost always fatal complication in diffuse large B-cell lymphoma patients. Optimal therapy for central nervous involvement in this malignancy has not been established. In this paper, we aimed to evaluate the therapeutic effect of E7123, a celecoxib derivative that inhibits focal adhesion signaling, in a novel xenograft model of diffuse large B-cell lymphoma with central nervous system involvement. Cells obtained after disaggregation of HT subcutaneous tumors (HT-SC cells) were intravenously injected in NOD/SCID mice. These mice received oral vehicle or 75 mg/kg of E7123 daily until they were euthanized for weight loss or signs of sickness. The antitumor effect of E7123 was validated in an independent experiment using a bioluminescent mouse model. Intravenously injected HT-SC cells showed higher take rate and higher central nervous system tropism (associated with increased expression of beta 1-integrin and p130Cas proteins) than HT cells. The oral administration of E7123 significantly increased survival time in 2 independent experiments using mice injected with unmodified or bioluminescent HT-SC cells. We have developed a new xenograft model of diffuse large B-cell lymphoma with central nervous system involvement that can be used in the pre-clinical evaluation of new drugs for this malignancy. E7123 is a new, well-tolerated and orally available therapeutic agent that merits further investigation since it may improve current management of diffuse large B-cell lymphoma patients with central nervous system involvement.

Citació

Citació

BOSCH, Rosa, MORENO JIMÉNEZ, María josé, DIÉGUEZ GONZÁLEZ, Rebeca, CÉSPEDES, María virtudes, GALLARDO, Alberto, TRIAS, Manuel, GRAÑENA BATISTA, Alberto, SIERRA GIL, Jorge, CASANOVA RIGAT, Isolda, MANGUES BAFALLUY, Ramon. A novel orally available inhibitor of focal adhesion signaling increases
survival in a xenograft model of diffuse large B-cell lymphoma with
central nervous system involvement. _Haematologica_. 2013. Vol. 98, núm. 8, pàgs. 1242-1249. [consulta: 24 de gener de 2026]. [Disponible a: https://hdl.handle.net/2445/126453]

Exportar metadades

JSON - METS

Compartir registre